• CTCF Maintains Centromere Function in Mitosis

  2026-09-23

  Rapid CTCF degradation in human cells disrupts centromere-associated functions, broadens and disorganizes the metaphase plate, and increases mitotic failure. The findings distinguish CTCF loss from a simple defect in CENP-E recruitment and support a role for CTCF in maintaining centromere mechanics and postmitotic nuclear shape.

• Berberine Hydrochloride at the AKI–Metabolism Interface

  2026-09-23

  Berberine hydrochloride offers a practical entry point for studying AMPK-linked metabolic regulation, lipid handling, apoptosis, and ferroptosis. This article outlines how translational teams can responsibly evaluate its relevance to acute kidney injury by connecting metabolic readouts with the oxidized self-DNA–STING–NLRP3 axis while distinguishing established evidence from forward-looking hypotheses.

• RUNX2 Epigenetic Resistance in Osteosarcoma

  2026-09-22

  This study identifies a RUNX2–NCOR1–HDAC3 repressor complex as an epigenetic brake on cGAS–STING–IFN-I signaling in osteosarcoma. The findings provide a mechanistic rationale for combining HDAC3 inhibition with anti-PD-1 therapy to address immune checkpoint blockade resistance in preclinical models.

• Canagliflozin Remodels Mitochondria in Diabetic Kidneys

  2026-09-22

  The 2025 reference study shows that Canagliflozin improves proximal tubular mitochondrial architecture and bioenergetics in hypertensive–diabetic mice, with stronger functional effects in males than females. Its findings support mitochondrial remodeling as a potential contributor to renal protection beyond glucose lowering and provide a framework for sex-aware kidney disease research.

• Canagliflozin Remodels Mitochondria in Diabetic Kidneys

  2026-09-21

  A 2025 study found that canagliflozin improved proximal tubular mitochondrial architecture and bioenergetics in hypertensive–diabetic mice, with stronger effects in males than females. The work positions mitochondrial remodeling as a candidate mechanism for renal protection beyond blood-glucose lowering and provides a framework for sex-aware diabetic kidney disease experiments.

• Anagliptin (SK-0403) Vascular Assay Workflow

  2026-09-21

  Anagliptin (SK-0403) is a selective DPP-4 probe that connects incretin biology with direct vascular smooth-muscle experiments. This workflow translates evidence for Kv channel modulation and SERCA pump regulation into practical assay design, controls, and troubleshooting steps.

• Talabostat mesylate in CARD8 Pyroptosis Research

  2026-09-20

  Talabostat mesylate, also called PT-100 or Val-boroPro, connects dipeptidyl peptidase inhibition with state-dependent CARD8 pyroptosis in human T cells and FAP-focused cancer assays. This guide translates those findings into practical workflows, controls, readouts, and troubleshooting strategies for immune and tumor-microenvironment studies.

• ddhCTP: Antiviral Assay Workflows

  2026-09-19

  ddhCTP provides a mechanistically focused way to test viral RNA synthesis interruption, especially in flavivirus polymerase and HEK293T cell antiviral assays. This guide separates direct chain termination from broader viperin activity and translates recent coronavirus findings into practical assay controls.

• Icatibant in Viral Infections: Mechanism and Evidence

  2026-09-18

  The 2023 letter by Mustonen and colleagues proposes bradykinin B2-receptor blockade as a host-directed strategy for severe hantavirus disease, linking two PUUV case reports with emerging COVID-19 trial evidence. Its main contribution is mechanistic and hypothesis-generating rather than confirmatory: icatibant may help address capillary leak, but timing, patient selection, and controlled efficacy data remain unresolved.

• Talabostat Mesylate (PT-100): DPP4/FAP Research

  2026-09-18

  Talabostat mesylate, also called PT-100 or Val-boroPro, is an orally active dipeptidyl peptidase inhibitor used to study DPP4/FAP biology. Its strongest value is mechanistic: it enables controlled investigation of protease-dependent immune, stromal, and hematopoietic responses, while available tumor-growth evidence remains model-dependent and limited.

• AICAR: AMPK Activation in Metabolic Research

  2026-09-17

  AICAR is a cell-permeable AMPK activator used to study energy metabolism regulation, inflammatory signaling, and cellular stress protection. Its preclinical value is strongest when pathway engagement, cytokine responses, viability, and model-specific limitations are measured together.

• Ertugliflozin (PF-04971729) Research Workflow

  2026-09-17

  Build reproducible renal transport, diabetes mellitus research, and inflammation-model workflows with the highly selective SGLT2 inhibitor Ertugliflozin (PF-04971729). This guide connects assay setup and formulation control with translational cardiovascular evidence, while emphasizing practical troubleshooting and experimental boundaries.

• Z-WEHD-FMK: Practical Caspase Assay Guidance

  2026-09-16

  This scenario-based guide explains how Z-WEHD-FMK (SKU A1924) can help researchers distinguish inflammatory caspase activity from broader viability effects in cell-based assays. It covers solvent compatibility, protocol design, pyroptosis interpretation, and practical vendor-selection criteria.

• Molidustat (BAY85-3934) Hypoxia Assay Workflow

  2026-09-16

  Molidustat (BAY85-3934) enables controlled hypoxia-inducible factor stabilization for renal anemia, chronic kidney disease, and mechanistic hypoxia studies. This workflow connects HIF-PH inhibition with Septin4–VHL–HIF-1α biology while emphasizing dosing, solvent, and assay controls.

• Berberine Hydrochloride: Research Workflows

  2026-09-15

  Build reproducible metabolic, cancer, and inflammation assays with Berberine hydrochloride while controlling solubility, vehicle exposure, and pathway-specific readouts. This guide connects AMPK and lipid-metabolism workflows with a carefully bounded, hypothesis-generating extension into oxidized self-DNA and inflammasome research.

8076 records 1/539 page Next 12345 下5页 Last page